Endovasc and MIV link on drug-eluting stents
This article was originally published in Clinica
Executive Summary
Two companies have formed a deal aimed at boosting their prospects in the expected $6 billion market for drug-coated and drug-eluting stents. The licensing deal will result in the incorporation of Endovasc's PROstent prostaglandin E-1 (PGE-1) coating onto MIV Therapeutics' laser cut stent, the MIVT coronary stent delivery system.